2024-02-15 06:08:28 ET
Summary
- Teva Pharmaceutical has experienced a significant downturn in the last decade but has recently shown signs of recovery.
- The company has stabilized its operating income of around $3 billion for the past five years, but its large debt load is holding back shareholder value.
- Teva's revenue growth in 2023, driven by drugs like Austedo and Ajovy, indicates a potential turnaround, but the company still faces challenges with debt and interest payments.
I was recently reviewing Teva Pharmaceutical (TEVA) to see if they have turned any sort of corner. They, along with most generic drug makers, have struggled for basically the last decade. Here is a look at a Teva and a few of their competitors like Viatris (VTRS) and Taro (TARO) over the last decade:
Read the full article on Seeking Alpha
For further details see:
A Review Of Teva's Prospects